IPI Surfacing

Alloy Therapeutics

Errik Anderson

Errik Anderson, MBA, is a bioengineer, entrepreneur and investor who has launched seven venture-backed biotech companies in the last 20 years, including Alloy Therapeutics, Adimab, Compass Therapeutics, Alector, Arsanis and Avitide.

Anderson first worked in venture capital at Lehman Brothers Venture Capital and in marketing at Bristol-Myers Squibb. After earning his bachelor’s degree in economics at Dartmouth College, he studied bioengineering and business as a graduate student at Dartmouth’s Thayer School of Engineering and the Amos Tuck School of Business Administration. He graduated as a Tuck Scholar for outstanding academic achievement and is currently a member of Tuck’s board of advisors.

Currently, Anderson is CEO of Alloy Therapeutics and the founder and CEO of Ulysses Diversified Holdings, which supports entrepreneurs building companies that make the world a better place. Anderson has also worked with and invested in teams in tech, fintech, consumer, software, alternative energy, health IT and health care services.

University of Toronto & SGC

Aled Edwards

Aled Edwards, Ph.D., founded and leads the Structural Genomics Consortium (SGC), a public-private partnership in the biomedical research and pharmaceutical sector. The SGC generates research tools and knowledge to support basic science and early-stage drug discovery. Since 2004, the SGC has placed all its research output into the public domain without restriction, including without patents as a core principle. The SGC founded the YCharOS project, which is an open science reagent antibody characterization public-private partnership.

Edwards is also a professor and the Temerty Nexus Chair of Health Innovation and Technology at the University of Toronto. He has published over 200 papers and his teams have contributed over 4,500 structures to the Protein Data Bank as of 2021.

Harvard Medical School

Andrew Kruse

Andrew Kruse, Ph.D., is a professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His lab is focused on the study of G protein-coupled receptors (GPCRs) and other transmembrane proteins. His team uses synthetic camelid antibodies, or nanobodies, as tools to study transmembrane signaling and has developed a nanobody library, now available for nonprofit research from Kerafast.

Alongside Timothy Springer, Kruse co-founded IPI in 2017 and Tectonic Therapeutic, three years later. He now serves on Tectonic’s board of directors.

Kruse earned his Ph.D. in structural biology under Brian Kobilka at Stanford University. He received an Amgen Young Investigator Award in 2019 and the Alfred P. Sloan Research Fellowship in 2017 for impactful early-career research.

Institute for Protein Innovation

Rob Meijers

Rob Meijers, Ph.D. is senior director of the Antibody Platform at the Institute for Protein Innovation (IPI). 

Meijers previously was a group leader at the European Molecular Biology Laboratory (EMBL) in Hamburg, Germany, where he established a facility for protein preparation and characterization, one of the largest biophysical core facilities in Europe. At EMBL he also developed a research program to study immune and neuronal receptors — determining how the axon guidance protein netrin interacts with its canonical receptor DCC, and obtaining MHC class I protein structures that provided fundamental insights into peptide binding and exchange. 

At IPI, Meijers and his colleagues discover synthetic recombinant antibodies for cell surface receptors and their ligands, and collaborate with academic investigators who need antibody tools to answer fundamental biological questions.

University of Zurich

Andreas Plückthun

Andreas Plückthun, Ph.D., has been a professor of biochemistry at the University of Zürich since 1993. His interdisciplinary protein engineering lab has made important contributions in antibody engineering, scaffold engineering, directed evolution, GPCR engineering and targeted gene delivery.

Plückthun developed the first antibody expression in E. coli and the first fully synthetic antibody library. He’s developed repeat proteins as alternative scaffolds; ribosome display as an in vitro protein evolution method; directed evolution methods for stabilizing GPCRs; and a system of virus-like particles to deliver DNA to selected cells in the body.

He has been an inventor on more than 25 patent families and is co-founder of four companies: Morphosys AG, Molecular Partners AG, G7 Therapeutics and Vector BioPharma. He has written over 500 publications which have been cited over 50,000 times and received numerous awards, including the 2016 Christian-Anfinsen Award of the Protein Society.

Addgene

Meghan Rego

Meghan Rego, Ph.D. is the director of antibodies at Addgene. 

Rego received her Ph.D. from the University of Rhode Island, where she studied the molecular etiology of the cancer susceptibility syndrome Fanconi anemia. She then worked at a variety of biotechnology and pharmaceutical companies focused on therapeutic biologics. In 2016, she joined Addgene to help launch their viral vector service. In her current role as director of antibodies, Rego oversees Addgene’s recombinant antibody production and quality control platform.